Core Insights - Lisata Therapeutics has been awarded "Overall BioPharma Solution of the Year" for its innovative therapies targeting advanced solid tumors, marking the second consecutive year of recognition [1][4][5] - The company utilizes its proprietary CendR Platform technology to enhance the delivery and efficacy of anti-cancer drugs, addressing unmet medical needs in oncology [2][6] Company Achievements - Over the past year, Lisata has reported significant clinical trial results, including a 60.8% six-month progression-free survival rate in the ASCEND Phase 2b trial for metastatic pancreatic ductal adenocarcinoma, compared to 25% for placebo [3] - The iLSTA trial for locally advanced, non-resectable pancreatic cancer achieved a 60% overall response rate and a 100% disease control rate, showcasing the effectiveness of its therapies [3][8] Technology and Innovation - The CendR Platform allows for more effective tumor-targeted delivery of anti-cancer drugs by activating the CendR transport mechanism, which enhances the penetration of drugs into solid tumors [2][6] - Certepetide, an investigational drug developed by Lisata, is designed to improve the uptake of anti-cancer therapies and has received multiple designations, including Fast Track and Orphan Drug Designation for various cancers [7][8][9] Industry Context - The biotechnology sector is rapidly evolving, with innovations in gene therapies, precision medicine, and sustainable bio-manufacturing driving significant advancements in healthcare [4][5] - The BioTech Breakthrough Awards program highlights the importance of recognizing companies that contribute to transformative solutions in life sciences and biotechnology [5][10]

Company Overview - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [3] - The company's investigational drug, certepetide, is designed to enhance the targeting and penetration of anti-cancer drugs into solid tumors through a novel uptake pathway [3] Upcoming Presentation - David J. Mazzo, Ph.D., President and CEO of Lisata, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025 [1] - The on-demand recording of Dr. Mazzo's presentation will be available starting September 5, 2025, at 7:00 a.m. Eastern Time [2] Future Expectations - Lisata anticipates announcing numerous milestones over the next 1.5 years and believes its projected capital will fund operations into the fourth quarter of 2026 [3] - The company has established significant commercial and R&D partnerships based on its CendR Platform technology [3]

Core Viewpoint - Lisata Therapeutics, Inc. is set to report its financial results for Q2 2025 on August 7, 2025, and will host a conference call to discuss these results [1]. Group 1: Financial Reporting - The financial results for the second quarter ended June 30, 2025, will be announced after the close of trading on August 7, 2025 [1]. - A conference call will be held at 4:30 p.m. Eastern time on the same day to discuss the financial results [1]. Group 2: Conference Call Participation - Interested participants must register for the conference call via a provided link and will receive an email with dial-in options [2]. - Participants are encouraged to join the call 15 minutes early to avoid delays [2]. Group 3: Webcast Availability - A live webcast of the conference call will be available on Lisata's website and can be replayed for 12 months starting two hours after the call concludes [3]. Group 4: Company Overview - Lisata Therapeutics is focused on developing innovative therapies for advanced solid tumors and other serious diseases [4]. - The company's investigational drug, certepetide, aims to enhance the targeting and penetration of anti-cancer drugs in solid tumors [4]. - Lisata has established significant commercial and R&D partnerships based on its CendR Platform technology and anticipates announcing multiple milestones in the next 1.5 years [4]. - The company expects its capital to fund operations into Q4 2026, covering anticipated data milestones from ongoing and planned clinical trials [4].